Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
DNA topoisomerase I was purified to near homogeneity from a clonal line of human lymphoblastic leukemia cells, RPMI 8402, that is resistant to camptothecin, a cytotoxic alkaloid from Camptotheca acuminata, and compared with that of the parent wild-type cells. As assayed by relaxation of the supercoiled plasmid DNA and by formation of enzyme-linked DNA breaks, the purified enzyme from the resistant cells was shown to be greater than 125-fold as resistant to camptothecin as the wild-type enzyme, comparable to a cellular resistance index of about 300. Therefore, the cellular resistance appears to be due to the resistance of the enzyme. The amount of the immunoreactive enzyme protein in whole extract appeared to be reduced to less than half that of the wild-type enzyme. These results establish that DNA topoisomerase I is the cellular target of camptothecin and that DNA topoisomerase I is essential for the survival of mammalian cells.
D002166:Camptothecin / Q000494:pharmacology*; D002460:Cell Line; D004264:DNA Topoisomerases, Type I / Q000378:metabolism*; D004278:DNA, Superhelical / Q000187:drug effects; D004351:Drug Resistance; D006801:Humans; D007163:Immunosorbent Techniques; D007945:Leukemia, Lymphoid / Q000201:enzymology; D009154:Mutation; D009690:Nucleic Acid Conformation / Q000187:drug effects; D010449:Peptide Mapping; D010957:Plasmids
D004278:DNA, Superhelical; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin